Abstract:BackgroundCardiac troponin I (cTnI) is the preferred biomarker for the diagnosis and management of acute myocardial infarction (AMI). Measurement of high-sensitivity cardiac troponin I (hs-cTnI) is useful for the detection of previously missed minor myocardial injuries, the early diagnosis of acute myocardial infarction, the rational diagnosis of high-risk cardiovascular patients, and for clinical therapeutic decision-making and prognostic assessment. Despite the development of both laboratory-based and point-of-care (POC) cTnI assays, discrepancies in testing results between these platforms underscore the need for highly sensitive assays with commutable results across various clinical settings to enhance patient care.MethodsThis study employed biosensor technology to investigate the interaction between troponin I protein and four commercially available anti-troponin I antibodies (G-129-C, 19C7, Ab01, and Ab02), aiming to optimize assay performance. We evaluated the analytical characteristics of two hs-cTnI assays: YHLO iFlash 3000 for central laboratories and Drawray iStar 500 for POC settings. The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) were determined for each assay. A cohort of 650 healthy Chinese individuals (304 males and 346 females) was utilized to establish the 99 th percentile upper reference limits (URLs). Additionally, a Passing-Bablok analysis was conducted on 227 serum samples to assess the concordance between the two methods.ResultsKinetic analysis demonstrated that antibody Ab02 exhibited a 20-fold higher affinity compared to 19C7, while Ab01 displayed approximately a 2-fold higher affinity than G-129-C, despite both pairs recognizing the same troponin I epitope. The imprecision levels for iFlash 3000 and iStar 500 hs-cTnI assays were 3.82% and 3.30%, 2.62% and 3.08%, and 1.88% and 1.82% for low, medium, and high-level controls, respectively. The established LoB and LoD for iFlash 3000 and iStar 500 hs-cTnI assays were 0.12 ng/L and 0.22 ng/L, and 0.37 ng/L and 0.44 ng/L, respectively. The correlation between Drawray iStar 500 and YHLO iFlash 3000 assay results was robust (r= 0.9993) across a wide range of troponin I concentrations (0.12 - 39600 ng/L), with measurable concentrations above 50% (83.54%, 87.83%, and 79.77%) for the overall, male, and female cohort. The non-parametric 99 th percentile URL of iFlash 3000 hs-cTnI in the study cohort was 9.94 ng/L (90%CI 8.23-13.64 ng/L), with gender-specific variations observed. The coefficient of variation (%CV) at the 99 th percentile value was well below 10% for the overall, male, and female cohort (3.42%, 2.82%, and 3.64%).ConclusionsThe findings affirm that both iFlash 3000 and iStar 500 hs-cTnI assays meet the criteria for high sensitivity and exhibit a strong correlation in test results. This correlation suggests their potential for interchangeable use in diverse clinical settings, thereby enhancing patient management. The distinct gender-specific 99 th percentile URLs underscore the importance of tailored reference values in clinical assessments. The high precision and low limits of detection and quantitation further validate the reliability of these assays in the early diagnosis and management of AMI patients.

Diagnostic and prognostic value of cardiac troponin I assays in patients admitted with symptoms suggestive of acute coronary syndrome

Acute Phase Response and Non-Reproducible Elevated Concentrations with a High-Sensitivity Cardiac Troponin I Assay

Comparison of rapid test for high-sensitivity troponin I with laboratory high-sensitivity troponin T in patients with acute chest pain - a prospective monocentric study

Evaluation of clinical performance of cardiac troponin Ⅰ in diagnosis and prognosis of non-ST elevation acute coronary syndromes

Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia

Comparison of multiple high sensitivity cardiac troponin assays for early low risk rule out of myocardial infarction: SCORECARD

A-011 Single High-Sensitivity Cardiac Troponin I Compared to High-Sensitivity Cardiac Troponin T Measurement to Rule Out Acute Myocardial Infarction at Low Risk for 30-Day Adverse Events: CONTRAST Study

Performance of high-sensitivity cardiac troponin T versus I for the early diagnosis of myocardial infarction

Saturday, 31 August 2013

Clinical Impact of Using a More Sensitive Troponin Assay in Patients with Acute Chest Pain.

High Baseline High-Sensitivity Cardiac Troponin T Concentrations and Risk of Index Acute Myocardial Infarction

The analytical performance assessment and clinical practice of three sensitive cardiac troponin Ⅰ assays

Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome

A-017 Clinical Performance Evaluation of the Atellica IM High-Sensitivity Troponin I Assay to Aid in Risk Stratification for All-Cause Mortality and Major Adverse Cardiac Events

Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 h

Evaluation of the analytical and clinical performance of a high-sensitivity troponin I point-of-care assay in the Mersey Acute Coronary Syndrome Rule Out Study (MACROS-2)

Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction

Clinical profile of patients and sensitivity of troponin I in patients with and without acute coronary syndrome: An observational study

A-336 Comparative Evaluation of Homogeneous Point-of-Care and Central Laboratory Chemiluminescent Immunoassays for High-Sensitivity Cardiac Troponin I

Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome

Acute kidney injury in relation to high-sensitivity cardiac troponin T levels in the emergency department